Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Still awaiting official confirmation over HTEP (human tissue engineered products) transfer:

This article was originally published in Clinica

Executive Summary

Formal confirmation of the transfer of human tissue engineered products to the pharmaceuticals unit of the European Commission, and an associated change in regulatory orientation, did not happen at the Medical Devices Experts Group (MDEG) meeting in Luxembourg on April 12-13. It had been thought that a representative from the pharmaceuticals unit within Directorate F present would be present, but there is ongoing speculation that formal clearance to make the announcement was - and still is - awaited. The indications are that the Commission is to regulate human tissue engineered products, henceforth to be known as Advanced Therapies, alongside pharmaceuticals, thus dropping the concept of the separate "third pillar" of regulation.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT054870

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel